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Abstract
Context: The metabolic syndrome (MetS), in addition to its lipid, metabolic, and anthropomorphic
characteristics, is associated with a prothrombotic and the proinflammatory state. However, the
relationship of inflammatory biomarkers to MetS is not clear.
Objective: To study the association between a group of thrombotic and inflammatory biomarkers
and the MetS.
Methods: Ten conventional MetS risk variables and ten biomarkers were analyzed. Correlations,
factor analysis, hexagonal binning, and regression of each biomarker with the National Cholesterol
Education Program (NCEP) MetS categories were performed in the Family Heart Study (n = 2,762).
Results: Subjects in the top 75% quartile for plasminogen activator inhibitor-1 (PAI1) had a 6.9
CI95 [4.2–11.2] greater odds (p < 0.0001) of being classified with the NCEP MetS. Significant
associations of the corresponding top 75% quartile to MetS were identified for monocyte
chemotactic protein 1 (MCP1, OR = 2.19), C-reactive protein (CRP, OR = 1.89), interleukin-6 (IL6,
OR = 2.11), sICAM1 (OR = 1.61), and fibrinogen (OR = 1.86). PAI1 correlated significantly with all
obesity and dyslipidemia variables. CRP had a high correlation with serum amyloid A (0.6) and IL6
(0.51), and a significant correlation with fibrinogen (0.46). Ten conventional quantitative risk factors
were utilized to perform multivariate factor analysis. Individual inclusion, in this analysis of each
biomarker, showed that, PAI1, CRP, IL6, and fibrinogen were the most important biomarkers that
clustered with the MetS latent factors.
Conclusion: PAI1 is an important risk factor for MetS. It correlates significantly with most of the
variables studied, clusters in two latent factors related to obesity and lipids, and demonstrates the
greatest relative odds of the 10 biomarkers studied with respect to the MetS. Three other
biomarkers, CRP, IL6, and fibrinogen associate also importantly with the MetS cluster. These 4
biomarkers can contribute in the MetS risk assessment.
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Introduction
Metabolic syndrome (MetS) is a cluster of physiologic
markers that includes obesity, insulin resistance, dyslipi-
demia, and hypertension. The National Cholesterol Edu-
cation Program ATP III (NCEP) considers a
proinflammatory and prothrombotic state as characteris-
tic of metabolic syndrome (MetS) [1]. A group of biomar-
kers, products of proinflammatory and prothrombotic
states, may play an important role in the cascade of the
biochemical processes in the MetS development [2,3]. It
has been suggested that imbalance in the energy associ-
ated with obesity, can drive all aspects of MetS, including
the proinflammatory and prothrombotic states [3].
Inflammation and thrombosis are considered to influence
the pathogenesis of coronary heart disease. Inflammation
in general is associated with increased levels of leucocytes,
fibrinogen, and C reactive protein (CRP) as well as other
biomarkers. For example, Interleukin-6 (IL6) is consid-
ered an important inducer of the hepatic secretion of CRP.
Plasma levels of IL6 and CRP have been reported to pre-
dict type 2 diabetes in humans [4]. It is assumed that the
up-regulation of proinflammatory cytokines may trigger
an impaired endothelial response and the production of
other substances such as plasminogen activator inhibitor
1 (PAI1). The inflammation may serve as a stimulus to
control procoagulation factors, downregulate procoagu-
lants, and inhibit fibrinolysis [5-7].
Although several studies have used multivariate factor
analysis as a tool for characterizing MetS clusters of risk
variables [8-11], only a few have also included inflamma-
tory markers [10,12-14]. Sakkinen et al.[12] studied 322
nondiabetic elderly. The traits were 11 conventional MetS
risk variables and 10 procoagulation, inflammation and
fybrinolysis biomarkers. They found that PAI1 clustered
with the "body mass" latent factor while CRP, fibrinogen,
DDimer, and a few other biomarkers clustered as an
"inflammation" latent factor. PAI1 was also associated
with the "insulin/glucose" factor. They hypothesized that
obesity is related to impaired fibrinolysis. Meigs [9] com-
mented on the failure of inflammatory markers to con-
tribute substantially to the "body mass" factor, a
surprising finding considering the fact that CRP was
reported to be associated with BMI. For example, Laakso-
nen et al.[15] showed that middle-aged non-diabetic men
with CRP levels ≥ 3 mg/l at baseline (with low grade
inflammation), were 3 times more likely to develop MetS,
but the risk weakened when they adjusted the data for
BMI. Similar findings for three ethnicities were described
by Hanley et al.[14] (n = 1,087). They found PAI1 contrib-
uted to a "metabolic syndrome" factor, whereas fibrino-
gen and CRP contributed to an "inflammation" factor.
Also, Yudkin et al.[10] (n = 393) reported that fibrinogen,
CRP, and IL6 contributed together in a separate "inflam-
mation" factor, but with a very low contribution in the
"metabolic syndrome" factor. Recently, Tang et al.[13] uti-
lized two biomarkers as part of the risk factors for MetS.
Studying data in the Family Heart Study, they found factor
1 as the most representative of MetS where PAI1 was an
important contributor.
We studied ten conventional MetS risk variables in the
NHLBI Family Heart Study (Time 2, see Methods). Their
combinations in a multivariate factor analysis generated
factors of MetS. A subgroup of the conventional variables
in our study represented the set of the variables utilized to
qualitatively characterize MetS (NCEP definition, see
Methods). Consequently, the 10 conventional variables
served as a representative construct for MetS. Adding ten
prothrombotic and proinflammatory biomarkers in the
study provided an ample vision to assess the role of ten
biomarkers in the MetS cluster.
Methods
Sampled population
The NHLBI Family Heart Study (FHS-Time 2) is a family-
based study that investigates genetic and non-genetic
causes of coronary calcification, atherosclerosis, and car-
diovascular risk factors during a 2nd visit of selected FHS
families. The white cohort (n = 2,762, including 19 partic-
ipants with race undefined or "other") was recruited
through 2002–2003 at five centers. Details of this study
are reported elsewhere [16,17]. The exact numbers of sub-
jects analyzed varied, because some of the biomarker
assays were available only for a smaller group of partici-
pants (see the corresponding tables and figures for the
exact sample sizes).
Risk variables
Ten MetS conventional risk variables were studied: body
mass index (BMI, kg/m2), waist circumference (WAIST,
cm), waist to hip ratio (WHR), percent body fat (PBF),
fasting (≥ 12 hours) glucose (GLUC, mg/dl), high density
lipoprotein cholesterol (HDLC, mg/dl), tryglicerides (TG,
mg/dl), low density lipoprotein cholesterol (LDLC, mg/
dl), and systolic (SBP, mm Hg) and diastolic blood pres-
sure (DBP, mm Hg). PBF was measured as the bioelectric
impedance of the body and was calculated based on the
Lukaski formula [18]. The venipuncture blood samples
were drawn and collected at each field center. Blood bio-
chemistries were quantified at the Central Biochemistry
Laboratory at Fairview-University Medical Center in Min-
neapolis, MN, described in detail elsewhere [17].
Ten inflammatory, prothrombotic, or fibrinolysis biomar-
kers were tested for their contribution to the MetS, respec-
tively CRP, fibrin fragment D-Dimer (DDIMER),
fibrinogen, interleukin-2 soluble receptor alpha (IL2SR),
IL6, monocyte chemotactic protein 1 (MCP1), matrixNutrition & Metabolism 2007, 4:28 http://www.nutritionandmetabolism.com/content/4/1/28
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metalloproteinase (MMP3), PAI1, serum amyloid A
(SAA), and soluble intercellular adhesion molecule 1
(sICAM1) (Table 1). Eight of the biochemical assays on
the inflammatory markers were performed at the Labora-
tory for Clinical Biochemistry Research, University of Ver-
mont, Colchester, VT. PAI1 and fibrinogen assays were
performed at the Central Biochemistry Laboratory at Fair-
view-University Medical Center in Minneapolis, MN. The
following assays were carried out:
CRP (mg/l) was measured using the BNII nephelometer
from Dade Behring utilizing a particle enhanced immu-
nonepholometric assay. Intra-assay coefficient of varia-
tion (IACV) ranged from 2.3 – 4.4% and inter-assay
coefficient of variation (IRCV) ranged from 2.1 – 5.7%.
DDIMER (ug/ml) was measured using an immuno-turbi-
dimetric assay (Liatest D-DI, Stago) on the Sta-R analyzer
(Stago) [19].
Fibrinogen  (mg/dl) concentrations were quantified by
the STAR automated coagulation analyzer (Diagnostica
Stago), and the clotting method of Clauss [20]. In this
method, the level of fibrinogen is directly correlated to the
clotting time of a diluted plasma sample in the presence
of excess thrombin. Participants' fibrinogen results were
then validated based on control results. The IACV was 4%
and the IRCV was 4%.
IL2SR  (pg/ml) was measured by ultra-sensitive ELISA
(R&D Systems, Minneapolis, MN) [21]. IACV was 3.0%
and IRCV was 5.0%.
IL6 (pg/ml) a pro-inflammatory cytokine was measured
by ultra-sensitive ELISA (R&D Systems, Minneapolis, MN)
[22]. The IRCV was about 6.3%.
MCP1  (pg/ml) was measured using an ultra-sensitive
ELISA assay (Quantikine Human MCP-1 Immunoassay;
R&D Systems, Minneapolis, MN). The sample type used
was citrated plasma. The IACV and IRCV ranged 4.7–7.8%
and 4.6–6.7% respectively.
MMP3 (ng/ml) was measured by an ultra-sensitive, solid-
phase sandwich ELISA using a polyclonal antibody spe-
cific for both the pro- and active forms of MMP-3 (Quan-
tikine Human MMP-3 (total) Immunoassay; R&D
Systems, Minneapolis, MN). The IACV and IRCV ranged
from 5.7–6.4% and 7.0–8.6%, respectively.
PAI1 (ng/ml) assay is sensitive to free PAI1 (both latent
and active), but not PAI1 in complex with t-PA. It is done
as a two-site ELISA. The analytical CV for this assay was
3.47% [23-25].
SAA (mg/l) was measured with the BNII nephelometer
from Dade Behring utilizing a particle enhanced immu-
nonepholometric assay (N Latex SAA; Dade Behring Inc.,
Deerfield, IL). IACV ranged from 4.3–6.2% and IACV
ranged from 2.8–4.7%.
sICAM1 (ng/ml) was measured by an ELISA assay (Param-
eter Human SICAM-1 Immunoassay; R&D Systems, Min-
neapolis, MN). The laboratory CV was 5.0% [26,27].
Metabolic syndrome
A grouping of at least any 3 of the 5 following MetS cate-
gories beyond the NCEP defined thresholds in a subject,
was considered as a clinical expression of the NCEP MetS:
Abdominal obesity, given as large WAIST for men >102
cm and > 88 cm for women; high fasting GLUC ≥ 110 mg/
dl or medication for diabetes; high TG ≥ 150 mg/dl; low
HDLC < 40 mg/dl in men or < 50 mg/dl in women; high
blood pressure (SBP/DBP) ≥ 130/≥ 85 mm Hg or antihyper-
tensive medication use [1].
Statistical analysis
Variables of interest were expressed as mean ± SD (Table
1). In addition, four statistical techniques were applied to
investigate the contribution of 10 biomarkers onto the
Table 1: Participants' characteristics
Variables Mean Std.Dev.
FHS-T2 Whites (n = 2762)
Females (%) 55
AGE 2762 57 13
BMI 2761 28.9 5.7
WAIST 2758 98.9 16.3
WHR 2758 0.9 0.1
PBF 2385 33.1 9.4
GLUC 2362 99.8 21.7
HDLC 2747 48.8 14.4
LDLC 2694 110.6 33.2
TG 2749 144.3 93.7
SBP 2760 121 20
DBP 2760 70 10
CRP 2685 3.6 5.7
SICAM1 2726 247.8 79.0
MCP1 2615 196.6 91.7
FHS-T2 Whites subsample (n = 532)
FIBRINOGEN 415 284.9 62.1
PAI1 415 39.6 44.4
IL2SR 474 802.0 457.8
IL6 520 2.4 1.6
MMP3 525 16.9 11.1
SAA 516 6.8 18.8
DDIMER 532 0.4 0.4
Note: For the measurement units and the full name of each variable, 
see paragraph "Risk variables" in the Methods.Nutrition & Metabolism 2007, 4:28 http://www.nutritionandmetabolism.com/content/4/1/28
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conventional MetS risk variables clusters and/or to the
MetS categories.
First, the multivariate factor analysis was performed with
the FACTANAL function, with the maximum likelihood
estimate option and the "Varimax" rotation, in Splus ver-
sion 6.2 of Insightful Corp., Seattle, WA. This method was
performed first on 10 conventional MetS risk variables.
After, one biomarker was added in the analysis, subject to
the sample sizes available, to discover any cluster of each
biomarker onto the identified latent factors. The accept-
ance of an extra factor in the model was made by applying
two general rules, the p-value of the model had to be <
0.05, and the last factor had to have at least two contrib-
uting risk variables (with a contributing coefficient about
0.4 or above). We stopped beyond the 5-th factor because
the additional factors represented only single variables.
The contributing coefficients for the standardized varia-
bles correspond to correlation coefficients of the original
risk variables to the latent factors. A contributing coeffi-
cient value in the tables greater/equal to 0.4 was high-
lighted in bold and is considered as having a substantial
influence on the factor. In advance to factor analysis, dis-
tributions of all risk variables were checked for their fit to
a normal distribution. Variables BMI, WHR, HDLC, TG,
CRP, DDIMER, fibrinogen, IL2SR, IL6, MCP1, MMP3,
PAI1, SAA, and SICAM1, were natural log transformed.
GLUC was expressed as the inverse of a power transforma-
tion (1/GLUC2). Risk variables went also through covari-
ate adjustments, in a stepwise regression in SAS v. 9.1.3
for Linux OS, for age, age2, age3 and recruitment center,
within gender. The residuals were standardized to mean 0
and variance 1.
Second, Pearson correlations were produced on the above
preprocessed data, by using the PROC CORR of SAS
(Table 2).
Third, a binary association between the PRESENCE/
ABSENCE of a participant in the top 75% quartile, as well
as in the 50% of the data for each biomarker and if CLAS-
SIFIED/NOT with MetS was evaluated through logistic
regression (PROC LOGISTIC of SAS).
In addition, a graphical technique named "hexagonal bin-
ning" was implemented [28]. For its methodology,
results, and discussion see the Appendix.
Results
Participants between ages 30 and 93 had a mean BMI of
28.9 ± 5.68 (Table 1). PAI1 levels were relatively high
(39.58 ± 44.36) with an interquartile range (IR) of 46
between the 25% quartile (q25) and 75% quartile (q75)
(see Table 1 and Figure 1). The CRP mean level was 3.61
± 5.65. The distribution is shown in Figure 2 which indi-
cates an IR of CRP of 3.4 in a sample of 2,685 participants.
The central 50% of the data were more spread around the
mean for PAI1 than for CRP. Using the ratio of IR/SD we
found that fibrinogen, sICAM1, PAI1, IL6, and MMP3
compared to BMI, had a similar spread of the central 50%
of the data. In contrast, the central 50% of the data were
less spread around the mean compared to BMI for SAA,
CRP, DDIMER, IL2sr, and MCP1.
It is interesting to note that PAI1 correlated significantly
with all obesity variables (with BMI, 0.53; PBF, 0.51;
WAIST, 0.56), IL6 (0.49), dyslipidemia, even with SBP
and DBP, reaching almost the lowest but still significant
correlation with fibrinogen (Table 2). CRP had high cor-
relations with SAA, IL6, and fibrinogen. On the other
hand, correlations of sICAM1, MCP1, MMP3, and
DDIMER, did not pass a coefficient of 0.4 with any of the
19 other risk variables and had a general trend for lower
correlations (Table 2 and Figure 2).
The above correlation matrix reflected in the results of fac-
tor analysis. The factor analysis with "Varimax" rotation
on the 10 conventional risk variables produced 4 latent
factors. The first factor was a contribution of BMI, WAIST,
PBF, and more modest contributions of WHR and GLUC.
The second factor was mostly SBP and DBP contributions.
The third factor was contributed by TG, HDLC, with less
contribution of GLUC, LDLC, and PBF. The last factor rep-
resented a contribution of WHR and WAIST. The MetS
cluster of latent factors explained about 60% of the total
variance of the conventional risk variables.
Figure 3 is a compilation of different factor analyses. Each
biomarker was individually added in the factor analysis of
the MetS cluster. PAI1 had the strongest contribution
compared to other biomarkers (loading coefficients 0.53
in Factor 1 and 0.42 in Factor 3). CRP contributed mainly
in Factor 1. IL6 was quite similar in contribution as CRP.
When CRP and fibrinogen were combined in the MetS
factor analysis (data not shown) only in that case, CRP
and fibrinogen stood in a separate factor, and loading
coefficients were 0.8 for CRP and 0.56 for fibrinogen.
sICAM1 contributed in the lipid factor (Factor 3). The rest
of the biomarkers, DDIMER, IL2SR, MCP1, MMP3, and
SAA had a limited contribution to the factor analysis of
MetS cluster.
Figure 4 shows only a partial picture of the PAI1 relation-
ships to classical MetS risk factors, in particular to HDLC
and TG. Three variables presented in this figure, HDLC,
TG, and PAI1 represent standardized residuals after natu-
ral log transformation and adjustments (for details see the
paragraph of Statistical analysis in the Methods section).
A red color annotates PAI1 values above the 75th PAI1
percentile; a green color annotates PAI1 values below theN
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Table 2: Correlation matrix of 20 risk variables in the FHS-T2 Whites
FHS-T2 BMI PBF WAIST WHR GLUC LDLC HDLC TG SBP DBP CRP SICAM1 FIB PAI1 IL2SR IL6 MCP1 MMP3 SAA
P B F 0 . 7 3 ‡ -- -- -- - -- - ------ -
W A I S T 0 . 8 9 ‡ 0 . 7 0 ‡ - -- -- - -- - ------ -
WHR 0.52‡ 0.42‡ 0.74‡ - - - - - - - - - - - - - - -
GLUC -0.33‡ -0.24‡ -0.32‡ -0.27‡ - - - - - - - - - - - - - -
LDLC 0.01 0.07† 0.00 0.02 0.08† -- - -- - ------ -
HDLC -0.28‡ -0.22‡ -0.26‡ -0.22‡ 0.17‡ -0.02 - - -- - ------ -
TG 0.29‡ 0.27‡ 0.29‡ 0.28‡ -0.17‡ 0.09‡ -0.46‡ - - - - - - - - - - -
SBP 0.19‡ 0.17‡ 0.18‡ 0.14‡ -0.14‡ 0.07† 0.00 0.13‡ - - - - - - - - - -
DBP 0.05* 0.04 0.06† 0.08‡ -0.03 0.11‡ 0.04* 0.09‡ 0.69‡ - - - - - - - - -
CRP 0.35‡ 0.35‡ 0.37‡ 0.28‡ -0.15‡ 0.02 -0.13‡ 0.20‡ 0.15‡ 0.06† - ------ -
SICAM1 0.08‡ 0.08‡ 0.09‡ 0.11‡ -0.08‡ -0.05† -0.15‡ 0.11‡ 0.02 0.00 0 . 1 5 ‡ ------ -
FIB 0.28‡ 0.32‡ 0.32‡ 0.33‡ -0.13* 0.06 -0.19‡ 0.11* 0.14† 0.00 0.47‡ 0.12* ----- -
PAI1 0.53‡ 0.51‡ 0.56‡ 0.43‡ -0.37‡ 0.10* -0.39‡ 0.43‡ 0.25‡ 0.17‡ 0.28‡ 0.19‡ 0.16† ---- -
IL2SR 0.04 0.01 0.10* 0.11* -0.04 -0.10* -0.17† 0.08 0.03 -0.08 0.28‡ 0.33‡ 0.37* 0.02 --- -
IL6 0.37‡ 0.34‡ 0.39‡ 0.30‡ -0.30‡ 0.00 -0.23‡ 0.20‡ 0.16‡ 0.02 0.51‡ 0.28‡ 0.12 0.49† 0.32‡ - - -
MCP1 -0.14‡ -0.16‡ -0.16‡ -0.15‡ 0.08‡ -0.03 0.19‡ -0.20‡ -0.05* 0.00 -0.08‡ -0.16‡ -0.09 -0.26‡ -0.23‡ -0.30‡ - -
MMP3 -0.06 -0.08 -0.07 -0.07 0.05 -0.08 0.02 -0.09* 0.04 0.00 -0.05 0.02 0.26 -0.18 0.12† 0.06 0.01 -
SAA 0.20‡ 0.16† 0.19‡ 0.15‡ -0.11* 0.02 -0.01 0.10* 0.13† 0.07 0.60‡ 0.15† -0.28 0.06 0.21‡ 0.38‡ -0.06 0.06
DDIMER 0.01 0.01 0.03 0.05 0.02 -0.05 -0.01 0.00 0.02 -0.01 0.17† 0.04 0.2 0.12† 0.13† 0.16‡ -0.10* 0.12† 0.11*
*p < .05;†p < .01; ‡ p < .0001; Negative sign of GLUC correlations is result of GLUC transformation (see Methods)Nutrition & Metabolism 2007, 4:28 http://www.nutritionandmetabolism.com/content/4/1/28
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25th percentile; and a black color annotates the 50% cen-
tral data of PAI1 distribution. The locations of these
points in Figure 4 are dependent on the HDLC and TG val-
ues of the subjects. It is clear that TG values along with
PAI1 values increased while HDLC values decreased. This
is in distinct contrast with LDLC, which had little to no
significant correlations with most of the biomarkers stud-
ied.
The other graphical technique employed by us to better
understand relationships of MetS NCEP categories and
biomarkers is hexagonal binning. This technique helps
visually to better investigate the predictive evidence of
biomarkers to the NCEP MetS categories (see details in the
Appendix, and Figures 1 and 2). More than 25% of partic-
ipants were obese (with a BMI of 30 kg/m2 or greater). Of
them, from the BMI top 75% percentile only a subset,
16.3% classified with MetS. Another 18% of the data,
located in the BMI central 50%, classified with MetS. PAI1
showed a similar pattern as BMI. PAI1 fitted regression
line intersected with the 75% quartile line at the graphical
point of 3 MetS categories, confining 17.1% of the sample
with MetS, and an additional 15.7% with MetS between
q25 and q75 lines. Differently, the CRP fitted regression line
intersected with the CRP top 75% quartile line at the
graphical point of 1 MetS NCEP category. At CRP values
Hexagonal binning of MCP1, MMP3, PAI1, SAA, and sICAM1 against NCEP MetS categories (0–5) Figure 1
Hexagonal binning of MCP1, MMP3, PAI1, SAA, and sICAM1 against NCEP MetS categories (0–5). BMI was added in the figure 
only for comparison. At each sub-graph the following information is provided: top of the graph: n – the sample size studied for 
the particular biomarker; q25 – the raw value of biomarker at the 25th percentile, q50 – the 50th percentile, and q75 – the 75th 
percentile; bottom of the graph: regression equation of the fitted model for a biomarker on MetS NCEP categories; NCEP 
MetS categories: 0 – none of the 5 categories reached beyond the NCEP thresholds (see Metabolic syndrome paragraph in 
the Methods section); 1 – at least one of the 5 categories passed the NCEP thresholds; similarly, 5 – all 5 categories passed 
the MetS NCEP thresholds. Three horizontal dashed lines represented the 25% (gray color), 50% (green color), and the 75% 
(red color) quartiles of a biomarker distribution. (Details provided in the Results and in the Appendix). For presentation 
clarity, 1 data point above 2500 pg/ml for MCP1, and 3 data points above 100 mg/l for SAA were removed from the graph.
n=525, q25=9.5;q50=13.6;q75=20.6
PAI1
SAA SICAM1 BMI
n=2761, q25=25;q50=28.1;q75=31.9
n=415, q25=7.5;q50=20;q75=54.5
n=516, q25=2.3;q50=3.6;q75=6.1 n=2726, q25=196.1;q50=232.1;q75=282.5
MCP1 MMP3
n=2615, q25=151.7;q50=183.9;q75=224.2
MetS NCEP categories MetS NCEP categories MetS NCEP categories
MetS NCEP categories MetS NCEP categories MetS NCEP catergoies
MCP1 = 170 + 12.8 MetSc MMP3 = 17.3 - 0.17 MetSc PAI1 = 11.3 + 14.9 MetSc
SAA = 4.7 + 0.43 MetSc SICAM1 = 230.6 + 8.6 MetSc BMI = 24.6 + 2.1 MetScNutrition & Metabolism 2007, 4:28 http://www.nutritionandmetabolism.com/content/4/1/28
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4.2 mg/l or greater, 11.8% of the sample were classified
with MetS. A subsample (20.7%) classified with MetS was
represented by participants having CRP values between
q25 and q75 lines. IL6 and fibrinogen respectively confined
13.2% and 11.6% of the sample, with MetS and placed at
the top biomarkers' 75% percentiles. In contrast,
DDIMER and MMP3 had flat regression lines.
PAI1 had the highest odds (6.9, CI95 [4.2–11.2], p <
0.0001) and comparable with BMI odds (5.2, [4.3–6.2])
when participants were in the top 75% quartile and clas-
sified as having the NCEP MetS. Other biomarkers MCP1
(OR = 2.19, CI95 [1.8–2.6], p < 0.0001), CRP (OR = 1.89,
[1.6–2.3], p < 0.0001), IL6 (OR = 2.11, [1.4–3.1], p =
0.0002), sICAM1 (OR = 1.61, [1.4–1.9], p < 0.0001), and
fibrinogen (OR = 1.86, [1.2–2.9], p = 0.0066) had also
significant odds for participants being in the top 75%
quartile of the biomarker distribution and classified as
having the NCEP MetS. The association of biomarker val-
ues per participant within the corresponding central 50%
of the data and being classified with MetS, was significant
only for CRP (OR = 1.3, [1.1–1.5], p = 0.0007).
Discussion
Inflammation, procoagulation and fibrinolysis biomark-
ers have been recently hypothesized to be associated with
MetS [12] and the development of atherosclerosis [29]. In
our study, PAI1 represented an important contributor to
the obesity and lipids factors and associated with the
NCEP MetS. Similar to our findings, PAI1 had a signifi-
cant contribution in the "Metabolic syndrome" factor in
the Hanly et al.[14] and in the Tang et al.[13], and in the
"Body mass" and lesser in the "Insulin/glucose" factors in
Sakkinen et al. studies [12]. PAI1 was strongly associated
with MetS components such as BMI, TG, a homeostasis
model assessment of insulin resistance, hs-CRP, and
Hexagonal binning of fibrinogen (FIB), CRP, DDIMER, IL2SR, and IL6 against NCEP MetS categories (0–5) Figure 2
Hexagonal binning of fibrinogen (FIB), CRP, DDIMER, IL2SR, and IL6 against NCEP MetS categories (0–5). BMI was added in 
the figure only for comparison. (Details provided in the Results and in the Appendix). For presentation clarity 2 data points 
above 70 mg/l for CRP, and 1 data point above 6000 pg/ml for IL2SR were removed from the graph.
n=415, q25=241.6;q50=278.8;q75=317.6 n=2761, q25=25;q50=28.1;q75=31.9
BMI FIB CRP
n=2685, q25=0.8;q50=1.9;q75=4.2
DDIMER
n=532, q25=0.2;q50=0.3;q75=0.5
IL2sr
n=474, q25=545.4;q50=700;q75=915.6
IL6
n=520, q25=1.4;q50=1.9;q75=2.9
MetS NCEP categories MetS NCEP categories MetS NCEP categories
MetS NCEP categories MetS NCEP categories MetS NCEP categories
BMI = 24.6 + 2.1 MetSc FIB = 261.7 + 12.5 MetSc CRP =2.3 + 0.63 MetSc
DDIMER = 0.4 + 0.01 MetSc IL2sr = 732 + 29.2 MetSc IL6 = 1.7 + 0.34 MetScNutrition & Metabolism 2007, 4:28 http://www.nutritionandmetabolism.com/content/4/1/28
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alanine aminotransferase [30]. PAI1 prevents plasmin
generation and is considered a primary inhibitor of fibri-
nolysis [31], and of extracellular matrix degradation [32].
Similar to CRP, PAI1 is lowered by weight loss and drugs
that improve insulin sensitivity. PAI deficient mice were
resistant to diet induced obesity, explained by increased
energy expenditure [33]. PAI1 is induced by many proin-
flammatory and pro-oxidant factors. For example, TNFα
(tumor necrosis factor alpha) is an inducer of the
increased levels of PAI1 [34-37]. Transgenic mice with ele-
vated levels of PAI1 in plasma developed venous occlu-
sions [38]. Transgenic mice with overexpression of
human PAI1 were found to develop macrovascular coro-
nary thrombosis and subendocardial myocardial infarc-
tion [39]. Smith et al.[40] concluded that PAI1 together
with fibrinogen, DDIMER were associated significantly
with risk of CVD. Consequently, PAI1 has important func-
tions and is a biomarker that can increase the prediction
for MetS in addition to the conventional risk factors.
Mertens et al.[7] investigated the association of 5 biomar-
kers with the MetS as defined by the NCEP criteria in 520
overweight and obese subjects, concluded that PAI1 is a
true component of MetS. However, questions remain
open whether PAI1 genes contribute to the MetS develop-
ment or represent a step in the cascade of the biochemical
pathways of MetS. It has been proposed that as a result of
obesity and hypoxia white adipose tissue overspills
inflammation markers [41]. Skurk and Hauner [42]
reviewed obesity and impaired fibrinolysis and reported
that increased fat cell size and adipose tissue mass associ-
ate with higher offerings of PAI1 in circulation. Moreover,
Liang et al.[33] studying cultured adipocytes from PAI1
(+/+) and PAI1(-/-) mice, found that PAI1 deficiency had
a protective role against insulin resistance, and was also
associated with up- and down-regulation of some other
important genes.
Factor analysis of "conventional" MetS risk factors with the addition of an individual biomarker at a time Figure 3
Factor analysis of "conventional" MetS risk factors with the addition of an individual biomarker at a time. Colors coded are fac-
tor domains: blue – Factor 1 – obesity; orange – Factor 2 – blood pressure; yellow – Factor 3 – lipids; and gold – Factor 4 – 
central obesity. Reported are only factors where a biomarker contributed.
Risk CRP* CRP CRP SICAM1 FIB FIB PAI1 PAI1 PAI1 IL2SR IL6 IL6 IL6 MCP1 MCP1 MMP3 SAA SAA DDIMER
variables Factor1 Factor3 Factor4 Factor3 Factor1 Factor3 Factor 1 Factor2 Factor3 Factor4 Factor1 Factor3 Factor4 Factor1 Factor3 Factor1 Factor1 Factor2 Factor1-4
BMI 0.96 0.17 0.95 0.17 0.93 0.11 0.17 0.95 0.12 0.94 0.18 0.95 0.92
PBF 0.75 0.11 0.16 0.74 0.15 0.74 0.16 0.12 0.73 0.15 0.73 0.17 0.72 0.71
GLUC -0.32¶ -0.13 -0.14 -0.18 -0.41 -0.13 -0.40 -0.19 -0.41 -0.20 -0.30 -0.18 -0.40 -0.40
LDLC † 0.12 0.10 0.20 0.16 0.21 0.14 0.14 0.13
HDLC -0.23 -0.47 -0.62 -0.31 -0.53 -0.30 -0.55 -0.13 -0.19 -0.64 -0.20 -0.60 -0.18 -0.11
TG 0.21 0.84 0.69 0.27 0.71 0.25 0.67 0.20 0.70 0.19 0.70 0.17 0.15
SBP 0.17 0.23 0.12 0.24 0.73 0.13 0.13 0.15 0.13 0.16 0.85
DBP 0.94 0.84
WAIST 0.90 0.34 0.14 0.95 0.11 0.910 0.13 0.50 0.90 0.37 0.88 0.15 0.89 0.86
WHR 0.49 0.87 0.18 0.66 0.18 0.53 0.19 0.72 0.46 0.10 0.88 0.46 0.17 0.44 0.44
C R P 0 . 3 5 0 . 1 4 0 . 1 0 - -- --- - --- -- - -- -
S I C A M 1 - ‡ -- 0 . 1 7 -- --- - --- -- - -- -
F I B --- - 0 . 3 3 0 . 1 5 --- - --- -- - -- -
P A I 1 --- - -- 0.53 0.18 0.42 - --- -- - -- -
IL2SR - - - - - - - - - 0.167 - - - - - - - - -
IL6 - - - - - - - - - - 0.39 0.23 0.12 - - - - - -
M C P 1 --- - -- --- - ---- 0 . 1 1 - 0 . 2 5 - -- -
M M P 3 --- - -- --- - --- -- - 0 . 1 1 -- -
S A A --- - -- --- - --- -- - 0 . 2 3 0 . 1 0 -
D D I M E R --- - -- --- - --- -- - -- 0
Variance (%) 26.1 9.3 8.3 9.4 29.9 8.9 28.8 13.5 10.4 7.7 25.9 9.7 8.8 23.7 9.7 23.3
N 1941 1967 310 310 333 372 1882 373 367 378
*Each "conventional" MetS factor analysis was performed with one biomarker at a time. We report only factors where a biomarker contributs to a factor (see Methods);  
†Loading values less than 0.1 are not shown; ‡This biomarker is not included in the analysis; ¶ The negative sign of GLUC loading is results of its distribution transformation Nutrition & Metabolism 2007, 4:28 http://www.nutritionandmetabolism.com/content/4/1/28
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A large number of studies have scrutinized the role of
CRP. Bassuk et al.[4], Ridker et al.[43], and Biasucci et
al.[44] summarized that CRP predicts incident myocardial
infraction, stroke, peripheral arterial disease, sudden car-
diac death, and confers additional prognostic value at all
levels of MetS. In contrast, Lloyd-Jones and Greenland
[45] argued that there is no advantage in adding CRP to
the standard risk model for coronary vascular disease
(CVD). The CRP predictive values were also explored by
Pankow et al.[46] who found that BMI, WHR and the
prevalent diabetes together explained 30% and 22% of
inter-individual variability in the CRP levels respectively
in women and men. In our study CRP contributes a small
fraction to the obesity factor (a loading of 0.35) and less
to the lipids factors (a loading of 0.14). Quite the oppo-
site, CRP clustered well in an independent latent factor
with fibrinogen (a loading of 0.8, data not shown). The
trends in our correlation findings for CRP matched with
the ones found in other publications. For example, CRP
had a high correlation 0.47 (Sakkinen et al.[12]) and 0.5
(Hanley et al.[14]) with fibrinogen, as two markers of the
acute-phase response.
Another interesting biomarker with significant findings in
our data was IL6. On severe exercise, IL6 is released in
large quantities from the skeletal muscle [47]. IL6 has
been suggested to be involved in the insulin sensitivity in
mice [48,49], and recently it is suggested that IL6 might
influence glucose tolerance [50,51]. Elevated levels of IL6
are found to be a predictor of CVD [52]. In our data, IL6
A three-dimensional presentation of relations among PAI1, HDLC, and TG, which accounts for only a small number of rela- tionships of PAI1 with the classical risk factors of MetS Figure 4
A three-dimensional presentation of relations among PAI1, HDLC, and TG, which accounts for only a small number of rela-
tionships of PAI1 with the classical risk factors of MetS. The three variables were natural log transformed and adjusted for a 
few covariates (for details see Statistical analysis paragraph in the Methods section). Red points represent the upper 25th 
percentile based on PAI1 values. Green points represent the lower 25th percentile, and in black are the 50% central PAI1 val-
ues. The higher TG values in a subject were associated with a lower HDLC value and also with a trend of increased values of 
PAI1.
Scatte p ot 3
High Density Lipoprotein 
Cholesterol
Triglycerides
Green points represent the ≤ 25 
percentile of PAI1 variable
Black points represent the 50% 
of central points of PAI1 variable
Red points represent the ≥ 75 
percentile of PAI1 variableNutrition & Metabolism 2007, 4:28 http://www.nutritionandmetabolism.com/content/4/1/28
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contributed to obesity and less to the lipids factor. A
unique finding was a high correlation between IL6 with
CRP, and PAI1, and lower although significant with BMI,
GLUC, WAIST, WHR, and SAA.
sICAM1 is an important adhesion molecule and is impli-
cated to mediate the firm adhesion of leukocytes into
endothelium [53]. sICAM1 in our data correlated posi-
tively and significantly with PAI1 and CRP. Other studied
biomarkers such as MCP1, SAA, and IL2SR had significant
correlations with CRP. Of them, SAA is an acute-phase
protein that exhibits a strong rise in blood in response to
inflammation. In our data the SAA response to inflamma-
tion was depicted with its highest significant correlation
(0.6) to CRP, but was not associated with MetS.
It has been hypothesized that a chronic, mild inflamma-
tory state is the ground of MetS. Besides, Dancan and
Schmidt [54] suggested that chronic activation of the
innate immune system can be related to MetS. Recently,
Forsythe  et al.[55] showed that low carbohydrate diet
decreased greatly TNF-α, IL6, IL8, MCP1, ICAM, and PAI1.
Based on these and several other reported facts, we specu-
late that some of these biomarkers are not only biochem-
ical steps in the cascades of inflammation, fibrinolysis and
prothrombosis, but also markers of obesity and dyslipi-
demia. DDIMER and MMP3 in our data could not be used
as direct predictors of the NCEP MetS, while PAI1, CRP,
IL6, and fibrinogen can convey additional information on
individuals classified with MetS. In particular PAI1, a key
component in the biochemical cascade of fibrinolysis,
may simultaneously influence fibrinolysis and coagula-
tion which may contribute in the arterial remodeling and
in the atherogenesis [29].
To our surprise, LDLC was not a good measure of the rela-
tionships with the biomarkers studied. Its correlation
coefficients with biomarkers were practically insignificant.
Therefore, we would suggest that future studies of MetS
use HDLC and TG as more reliable measures for the lipids
component.
Our study has also limitations. We studied only 10
biomarkers. Their sample size depended on the cost of the
biochemical assays. We have previously reported that
about 25% of the FHS Time 2 participants studied used
anti-hyperlipidemics, and that these medications were a
confounder when studying the MetS prevalence [56]. It is
known that such treatments affect concentrations in
plasma of a few biomarkers studied. However, at present
no medication summaries for biomarkers were available
and thus, unfeasible to account for those effects.
In conclusions, PAI1 significantly correlated with most of
the MetS conventional variables. PAI1 clustered in obesity
and lipids factors, and participants in the PAI1 top 75%
percentile had higher odds, than other 9 biomarkers, to be
classified with MetS. PAI1 is an important risk factor for
MetS. Three other biomarkers, CRP, IL6, and fibrinogen
associate importantly with MetS cluster. In contrast
DDIMER, SSA, and MMP3 did not associate directly with
MetS cluster.
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Appendix
Hexagonal binning in our MetS study: Why it appeals as a 
reductionist technique
To the best of our knowledge, hexagonal binning is a tech-
nique that is not implemented in the epidemiological
studies including MetS studies. It is applied in other areas
of research, for example, earthquake graphical pattern
detections [28]. Its main strength is in dealing with large
datasets to clarify their spatial structure. The hexagonal
binning technique was applied on the original data by cre-
ating larger units (16 bin counts per biomarker relative to
its sample size) to reduce the dimensionality. Hexagon
sizes (shown on the side of the graphs) within the Figures
1 and 2 represent the relative frequencies of subjects with
similar biomarker values. This method was used to clarify
the spatial structure of biomarkers against 0 to 5 catego-
ries of the NCEP MetS, while maintaining a measure of
data density. The 0th MetS NCEP category refers to the fact
that none of the 5 NCEP MetS definition thresholds was
passed in a subject. The 1st category represents that at least
one of the 5 thresholds was passed; similarly, the 5th MetS
NCEP category it means that five of the MetS NCEP defi-
nition thresholds were passed in a subject (see Metabolic
syndrome paragraph in the Methods section). In the hex-
agonal binning graphs (see Figures 1 and 2), three hori-
zontal dashed lines represent the 25% (gray color), 50%
(green color), and the 75% (red color) quartiles of a
biomarker distribution. A regression line of the original
biomarker values on MetS categories (0–5), together with
its corresponding equation placed at the lower position of
each graph helped to better understand the trend of the
relation between a biomarker and MetS categories. To
facilitate graphical perception and comparison, the BMI
graph in relation to MetS categories was added in both
Figures 1 and 2. Observations from the graphs in each fig-
ure show: (a) the densest distribution of subjects with 3 or
more categories beyond the NCEP MetS definition thresh-
olds; (b) the trend of the frequencies of subjects with MetS
change in relation to the increasing values of a biomarker.
The regression line between NCEP MetS categories and a
specific biomarker adds information to the trends
detected. For example, in the case of DDIMER and MMP3,
most of subjects classified with MetS were heavily concen-
trated within q25 and q75 quartiles values of each of theseNutrition & Metabolism 2007, 4:28 http://www.nutritionandmetabolism.com/content/4/1/28
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biomarkers, but the biomarker relation trend with catego-
ries of MetS remained flat. This reinforced our previous
conclusions that with the studied sample it is less proba-
ble that DDIMER and MMP3 contributed in the develop-
ment or were associated with MetS. In the BMI graph one
can see that the frequency of subjects with MetS increased
as the BMI values augmented. From the Figure 1 it is clear
more than half of the subjects with BMI above 31.9 (q75)
were classified with MetS. Although a small group of sub-
jects were with BMI less than 25 (q25), they also were clas-
sified with MetS. This shows that MetS is not only result of
obesity in combination with other components of MetS,
but it can also be a hypertension-dyslipidemic-hyperglyc-
emic combination. For the PAI1 biomarker, (Figure 1),
subjects with PAI1 greater than 54.5 (q75) were predomi-
nantly classified with MetS. In conclusion, hexagonal bin-
ning was a spatial graphical attempt to better characterize
and understand the contributions of each biomarker stud-
ied in relation to MetS NCEP categories.
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